Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Alex Godwood"'
Autor:
Pradeep J. Nathan, S. Babli Millais, Alex Godwood, Odile Dewit, David M. Cross, Janet Liptrot, Bharat Ruparelia, Stephen Paul Jones, Geor Bakker, Paul T. Maruff, Gregory A. Light, Alastair J.H. Brown, Malcolm Peter Weir, Miles Congreve, Tim Tasker
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 8, Iss 1, Pp n/a-n/a (2022)
Abstract Introduction This study examined the safety and pharmacodynamic effects of selective muscarinic M1 receptor orthosteric agonist HTL0018318 in 60 patients with mild‐to‐moderate Alzheimer's disease (AD) on background donepezil 10 mg/day. M
Externí odkaz:
https://doaj.org/article/d2ea8035b82442a48e018eec2348acbe
Autor:
Pradeep J, Nathan, S Babli, Millais, Alex, Godwood, Odile, Dewit, David M, Cross, Janet, Liptrot, Bharat, Ruparelia, Stephen Paul, Jones, Geor, Bakker, Paul T, Maruff, Gregory A, Light, Alastair J H, Brown, Malcolm Peter, Weir, Miles, Congreve, Tim, Tasker
Publikováno v:
Alzheimer'sdementia (New York, N. Y.). 8(1)
This study examined the safety and pharmacodynamic effects of selective muscarinic MA randomized, double-blind, placebo-controlled 4-week safety study of HTL0018318 with up-titration and maintenance phases, observing exploratory effects on electrophy
Autor:
Alex Godwood, Pradeep J. Nathan, Jan Booij, Oswald J.N. Bloemen, Matthan W.A. Caan, Claudia Vingerhoets, Therese van Amelsvoort, Geor Bakker
Publikováno v:
Alzheimer's & Dementia. 15:P968-P968
Publikováno v:
Investigational New Drugs. 27:253-261
Background: Vandetanib (ZACTIMA™) is a once-daily oral inhibitor of vascular endothelial growth factor, epidermal growth factor and RET receptor tyrosine kinases. The safety and tolerability of vandetanib plus mFOLFOX6 was investigated in patients
Autor:
Michael Lundgren, Björn Tilling, Dee Gor, Sverker Jern, Lars-Erik Adolfsson, Christina Tyren, Alex Godwood
Publikováno v:
Clinical Drug Investigation. 25:231-241
The incidence of asthma exacerbations in patients receiving salmeterol/fluticasone propionate (Seretidetrade mark or Advair((R))) is low. However, when asthma control deteriorates, clinicians may instruct patients to double the dose of their inhaled
Publikováno v:
Clinical Drug Investigation. 25:1-11
Background and objective: Salmeterol and fluticasone propionate are well established in the treatment of childhood asthma, and their combination is effective in children aged 4–11 years. Asthma guidelines recommend that the inhaler device best suit
Autor:
Eric Van Cutsem, Marc Peeters, Mark P. Saunders, Stuart Oliver, Richard H. Wilson, Robert Smith, Alex Godwood
Publikováno v:
Cancer chemotherapy and pharmacology. 64(4)
The safety and tolerability of vandetanib (ZACTIMA™; ZD6474) plus FOLFIRI was investigated in patients with advanced colorectal cancer (CRC). Patients eligible for first- or second-line chemotherapy received once-daily oral doses of vandetanib (100
Autor:
Mary Thompson, P Morris, Alex Godwood, Christine Royston, PC Roberts, Pierre J. Willemse, K D Bardhan, Caroline Shaw, Anne Rowland, Hilary Allen, Darren Morton
Publikováno v:
Gastroenterology. 120:A585